Value and Access Strategy

Demonstrating the value of medicines in rare diseases is complex; the burden of disease is poorly documented and lack of disease specific therapeutic options which means the decision context is often unclear.

The bedrock that underpins our approach is developing a deep understanding of the decision process whilst ensuring development of the value strategy remains aligned with commercial and clinical objectives.


Our value and access offerings include:

Value & Access

MASS Team - Value and Access

  • Value strategy development

  • Value proposition development

  • Value dossiers

  • Value demonstration

  • Budget impact models

  • Pre-launch pricing strategy

  • Modified Delphi Panels

  • HTAs, pricing and reimbursement submissions

Contact us to see how the MASS Team can work with you to develop and deliver value strategies for your rare disease brand.

For more about MASS Team’s Value & Access Strategy